PATENT CLAIM ANALYSIS

Application Number: 15759305
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Claim (Index 5):
The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to  claim 2 , wherein the antisense oligomer (d) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 95 (NMS-38), SEQ ID NO: 96 (NMS-39), SEQ ID NO: 107 (NMS-66), SEQ ID NO: 223 (NMS-223), SEQ ID NO: 234 (NMS-238), SEQ ID NO: 235 (NMS-239), SEQ ID NO: 242 (NMS-246), SEQ ID NO: 249 (NMS-253), SEQ ID NO: 250 (NMS-254), SEQ ID NO: 251 (NMS-255), SEQ ID NO: 257 (NMS-268), SEQ ID NO: (NMS-280), SEQ ID NO: (NMS-281), SEQ ID NO: (NMS-282), SEQ ID NO: (NMS-288), SEQ ID NO: (NMS-289), SEQ ID NO: (NMS-290), SEQ ID NO: (NMS-292), SEQ ID NO: (NMS-293), SEQ ID NO: (NMS-294), SEQ ID NO: (NMS-295), SEQ ID NO: (NMS-298), SEQ ID NO: (NMS-299), SEQ ID NO: (NMS-300), SEQ ID NO: (NMS-302) and SEQ ID NO: (NMS-303).

Metadata:
- Claim Count in Document: 8.0
- Percentile: 90.0
- Lexical Diversity: 1.38889
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15759267', '15314535', '14368307', '15122435', '15339069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.850409358583998
- 35 USC 102 Novelty (BERT): 0.5626727788185764
- Combined Prediction Score: 0.8216357006074558
- Mean Citation Score: 427.308318
- Max Citation Score: 475.8151
- Similarity Product: 350.567838809514

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test